Lates News

Pfizer announced that the world's first innovative drug, Trazimab (generic name: emicizumab), which requires only a fixed dose subcutaneous injection once a week, has been officially approved by the China National Medical Products Administration for the routine prevention and treatment of heavy A-type hemophilia without factor VIII inhibitors or heavy B-type hemophilia without factor IX inhibitors in children and adults aged 12 years and older who weigh 35kg, to prevent bleeding or reduce the frequency of bleeding episodes.